The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence

JM Witkin, MA Statnick, LM Rorick-Kehn… - Pharmacology & …, 2014 - Elsevier
Nociceptin/Orphanin FQ (N/OFQ) is a 17 amino acid peptide that was deorphanized in 1995.
The generation of specific agonists, antagonists and receptor deficient mice and rats has …

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

LM Rorick-Kehn, BG Johnson, KM Knitowski… - …, 2007 - Springer
… 1) with high in vitro potency and efficacy and improved rodent bioavailability (Monn et al.
2007; Rorick-Kehn et al. 2007) was evaluated for its ability to influence several in vivo effects …

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive …

LM Rorick-Kehn, JM Witkin, MA Statnick, EL Eberle… - …, 2014 - Elsevier
Kappa opioid receptors and their endogenous neuropeptide ligand, dynorphin A, are densely
localized in limbic and cortical areas comprising the brain reward system, and appear to …

The rapidly acting antidepressant ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits

…, B Johnson, K Rasmussen, LM Rorick-Kehn - … of Pharmacology and …, 2016 - ASPET
Ketamine is a rapidly acting antidepressant in patients with treatment-resistant depression (TRD).
Although the mechanisms underlying these effects are not fully established, inquiry to …

[HTML][HTML] Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models

…, BL Adams, CD Jesudason, LM Rorick-Kehn - Frontiers in …, 2014 - frontiersin.org
Rorick-Kehn are employees of, and stockholders in, Eli Lilly and Company. … Copyright ©
2014 Anderson, Becker, Adams, Jesudason and Rorick-Kehn. This is an open-access article …

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of …

LM Rorick-Kehn, BG Johnson, JL Burkey… - … of Pharmacology and …, 2007 - ASPET
Group II metabotropic glutamate (mGlu) receptor agonists, including (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate
monohydrate (LY354740) and (–)-2-oxa-4-…

A novel, orally bioavailable nociceptin receptor antagonist, LY2940094, reduces ethanol self‐administration and ethanol seeking in animal models

LM RorickKehn, R Ciccocioppo… - Alcoholism: Clinical …, 2016 - Wiley Online Library
… Rats were maintained on an arithmetic progressive ratio operant schedule with counterbalanced
active and inactive levers as previously described (Rorick-Kehn et al., 2014). Briefly, …

[HTML][HTML] Genetic deletion of the nociceptin/orphanin FQ receptor in the rat confers resilience to the development of drug addiction

…, F Weiss, MA Statnick, LM Rorick-Kehn… - …, 2017 - nature.com
The nociceptin (NOP) receptor is a G-protein-coupled receptor whose natural ligand is the
NOP/orphanin FQ (N/OFQ) peptide. Evidence from pharmacological studies suggests that the …

Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344

LM Rorick-Kehn, EJ Perkins, KM Knitowski… - … of Pharmacology and …, 2006 - ASPET
Numerous studies have indicated that selective agonists of group II metabotropic glutamate (mGlu)
receptors, such as LY354740 [(1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-…

Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human

LM Rorick-Kehn, JW Witcher, SL Lowe… - International Journal …, 2015 - academic.oup.com
Background: Selective kappa opioid receptor antagonism is a promising experimental
strategy for the treatment of depression. The kappa opioid receptor antagonist, LY2456302, …